Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I/II study of bleximenib in acute leukemia
CTR20244242Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bleximenib in Acute Leukaemia, acute myeloid leukemia (AML), sponsored by Janssen Pharmaceutical. Started Dec 2024; status: active.
02
Drugs
bleximenib
03
Conditions
Acute Leukaemiaacute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20244242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244242.